ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,039.12
0.41%
Dow Jones
38,065.10
0.43%
US Dollar vs MXN
16.93802
-0.03%
Brent Oil
83.605
0.08%
Bitcoin
59,053.02
1.40%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. ARS Pharmaceuticals Inc (SPRY)

  7. ARS Pharmaceuticals Inc (SPRY) Noticias

SPRY ARS Pharmaceuticals Inc

9.2106
-0.1194 (-1.28%)
Última actualización: 11:47:19
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
ARS Pharmaceuticals Inc SPRY NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.1194 -1.28% 9.2106 11:47:19
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
9.35 8.94 9.4909 9.33
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/4/202408:01GLOBEARS Pharmaceuticals Submits Response for neffy® (epinephrine..
03/4/202408:01GLOBEARS Pharmaceuticals Submits Response to FDA Complete..
21/3/202415:05GLOBEARS Pharmaceuticals Provides Business Update and Reports..
07/3/202415:05GLOBEARS Pharmaceuticals Reviews Recent Clinical Updates and..
07/3/202411:56EDGAR2Form 8-K - Current report
06/3/202408:01GLOBEARS Pharmaceuticals to Participate in the Leerink Partners..
01/3/202419:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202420:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202411:08EDGAR2Form 144 - Report of proposed sale of securities
26/2/202408:01GLOBEARS Pharmaceuticals announces neffy® meets primary endpoints..
22/2/202408:01GLOBEARS Pharmaceuticals to Host Virtual neffy® Investor Day on..
20/2/202408:01GLOBEARS Pharma Announces Favorable Topline Results from Repeat..
05/2/202408:01GLOBEARS Pharmaceuticals to Present Positive Clinical Efficacy..
04/1/202415:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202315:02EDGAR2Form 8-K - Current report
09/11/202315:00GLOBEARS Pharmaceuticals Reports Third Quarter 2023 Financial..
09/11/202310:02GLOBEARS Pharmaceuticals Announces Presentation of Clinical Data..
06/10/202308:57DJNARS Pharmaceuticals to Meet With FDA on Neffy Rejection
06/10/202308:03GLOBEARS Pharmaceuticals Announces Scheduling of a Type A Meeting..
03/10/202308:03GLOBESingle and Repeat Dose Clinical Study of neffy (epinephrine..
25/9/202315:17EDGAR2Form 8-K - Current report
20/9/202309:20DJNARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy..
20/9/202305:30DJNARS Pharmaceuticals Shares Sink Premarket as FDA Rejects..
20/9/202305:05EDGAR2Form 8-K - Current report
19/9/202321:49GLOBEFDA Issues Complete Response Letter for neffy® (epinephrine..
01/9/202315:15EDGAR2Form SC 13D/A - General statement of acquisition of..
10/8/202315:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202315:05EDGAR2Form 8-K - Current report
10/8/202315:00GLOBEARS Reports Second Quarter 2023 Financial Results and..
28/6/202320:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/6/202320:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/6/202315:32EDGAR2Form 8-K - Current report
20/6/202307:00GLOBEARS Pharmaceuticals Announces PDUFA Date Extension for..
15/5/202308:00GLOBEARS Pharmaceuticals Highlights Progress and Reports First..
12/5/202307:55DJNARS Pharmaceuticals Soar 68% in Premarket Trading as FDA..
11/5/202318:01GLOBEFDA Advisory Committee Votes in Support of Favorable..
09/5/202308:10GLOBEARS Pharmaceuticals Announces Availability of Briefing..

Su Consulta Reciente

NASDAQ
SPRY
ARS Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados